Zimmer Biomet's cervical disc implant labeling features 7-year clinical results: 5 things to know

Written by Mackenzie Garrity | October 01, 2018 | Print  |

The FDA granted Zimmer Biomet's request to extend its Mobi-C Cervical Disc labeling to include seven-year clinical results.

Here are five things to know:

1. The results are consistent with Zimmer Biomet's findings at two and five years.

2. At the seven-year mark, Zimmer Biomet found the Mobi-C disc was successful for two-level use when compared to anterior cervical discectomy and fusion.

3. Zimmer Biomet followed nearly 600 patients who were implanted with the Mobi-C disc for seven years. The study showed the disc was associated with lower pain scores. Patients maintained range of motion and fewer subsequent surgeries were necessary.

4. The Mobi-C is a cobalt chromium alloy and polyethylene mobile-bearing prosthesis that is inserted in a single step, without requiring bone chiseling to accommodate vertebral anchorage such as screws or keels.

5. The Mobi-C is the first cervical disc prothesis approved by the FDA for cervical disc reconstruction at one and two levels.

More articles on devices and implants:
Stryker to pay $7.8M to settle SEC Foreign Corrupt Practices Act violation charge: 5 things to know
Global thoracolumbar spine devices market to grow at 6.5% CAGR through 2023
4 things to know about RTI Surgical's CEO

© Copyright ASC COMMUNICATIONS 2019. Interested in LINKING to or REPRINTING this content? View our policies here.

Top 40 Articles from the Past 6 Months